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Background: Gamijinhae-tang (GJHT) has long been used in Korea to treat respiratory diseases. The therapeutic
effect of GJHT is likely associated with its anti-inflammatory activity. However, the precise mechanisms underlying
its effects are unknown. This study was conducted to evaluate the protective effects of GJHT in a porcine
pancreatic elastase (PPE) and lipopolysaccharide(LPS) induced animal model of acute lung injury (ALI).
Methods: In this study, mice were intranasally exposed to PPE and LPS for 4 weeks to induce chronic obstructive
pulmonary disease (COPD)-like lung inflammation. Two hours prior to PPE and LPS administration, the treatment
group was administered GJHT extracts via an oral injection. The numbers of neutrophils, lymphocytes, macrophages
and total cells in the bronchoalveolar lavage (BAL) fluid were counted, and pro-inflammatory cytokines were also
measured. For histologic analysis, hematoxylin and eosin (H&E) stains and periodic acid-Schiff (PAS) stains were
evaluated.
Results: After inducing ALI by treating mice with PPE and LPS for 4 weeks, the numbers of neutrophils,
lymphocytes and total cells were significantly lower in the GJHT group than in the ALI group. In addition, the IL-1β
and IL-6 levels were significantly decreased in the GJHT group. The histological results also demonstrated the
attenuation effect of GJHT on PPE- and LPS-induced lung inflammation.
Conclusions: The results of this study indicate that GJHT has significantly reduces PPE- and LPS-induced lung
inflammation. The remarkable protective effects of GJHT suggest its therapeutic potential in COPD treatment.
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Chronic obstructive pulmonary disease (COPD) is a
leading and increasing cause of morbidity and mortality.
Worldwide, it is projected to rise to rank fifth in disease
burden by 2020, and it now ranks as the third leading
cause of death in the USA [1,2]. COPD is characterized
by lung parenchyma destruction, mucus hypersecretion,
emphysema, an abnormal lung inflammatory response* Correspondence: jskes1@gmail.com; hbae@khu.ac.kr
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reproduction in any medium, provided the orto external stimuli, and progressive airflow limitation
[3-5]. The pathophysiology of airways in COPD involves
neutrophilic airway inflammation, antiprotease imbal-
ances, and oxidative stress [6]. The major cause of
COPD is cigarette smoking [1,7-10]. Tobacco contains
high levels of LPS, approximately 1% of which survives
combustion and is an active component of cigarette
smoke [11,12]. LPS is a major proinflammatory compo-
nent of gram-negative bacteria. In experimental animals,
the exposure of mice to inhaled LPS was shown to cause
emphysema-like changes that persisted up to 4 weeks
[13]. Recently, Sajjan et al. reported that PPE- and LPS-
treated mice exhibited pathological and physiological
changes typical of COPD, showing airway hyper-
responsiveness (AHR) and increased airway inflammationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mal model to better understand the therapeutic effects of
herbal medicines on COPD.
Gamijinhae-tang (GJHT) has been used to treat re-
spiratory diseases such as emphysema, bronchitis,
asthma, and COPD in Korea for centuries. GJHT con-
tains 16 species of medicinal plants [15,16]. In Korean
traditional medicine, medicinal plants are generally used
in mixtures. Medicinal plants have long been used to
treat inflammation and other inflammation-related dis-
eases, and the raw materials of these products are often
used to develop new drugs [17-20]. However, the pre-
ventative effects and underlying mechanisms of GJHT
on pulmonary disorders have not yet been evaluated. In
this study, we provide evidence that GJHT has potential
preventative effects on COPD.
Methods
Water extraction of Gamijinhae-tang (GJHT)
Sixteen medical herbs were used to prepare GJHT
(Table 1). All herbs were purchased from Omniherb
(Omniherb Co., Korea). A total of 258 grams of GJHT
was boiled in 1.4 liters of distilled water in an Herb Ex-
tractor (Dae-Woong Co., Korea) for 2 hr, yielding a final
580 ml of GJHT extract. The supernatant was harvested
under sterile conditions by centrifugation and was ly-





Rehmannia glutinosa Liboschitz var.
purpurea Makino
14 5-HMF
Raphanus sativus var. hortensis for.
acanthiformis MAKINO
14
Astragalus membranaceus Bunge. var.
membranaceus
9
Atractylodes macrocephala Koidz. 9
Poria cocos Wolff 5
Pinellia ternate (Thunb.) Breit. 5
Citrus unshiu Markovich 5 Hesperidin
Angelica gigas NAKAI 5 Decursin
Liriope platyphylla F. T. Wang & T. Tang 5
Platycodon grandiflorum A. De Candolle 5
Anthriscus sylvestris 5
Schisandra chinensis (Turcz.) Baill 5
Morus alba L. 5
Scutellaria baicalensis 5 Baicalin,
Baicalein
Sinapis semen 3
Glycyrrhiza uralensis FISCH 3
Total 100GJHT extract was dissolved in an appropriate volume of
sterile PBS prior to its administration to mice.
High performance liquid chromatography (HPLC) Analysis
of GJHT
5-Hydroxymethylfuraldehyde (5-HMF) was purchased
from Sigma Aldrich (Wisconsin, UA), and baicalin,
baicalein, hesperidin and decursin were purchased from
Wako Chemicals (Osaka, Japan). HPLC grade aceto-
nitrile was purchased from J. T. Baker (NJ, USA). A hun-
dred miligram of GJHT extract was dissolved in 1 ml of
methanol and distilled water (1:20) and extracted
through C18 SPE cartridge (Waters) to remove poly-
saccharides. Residual portions were recovered and dried
under nitrogen to yield 16.1 mg of residue. The residue
was dissolved in 1 ml of same solvent above. All stan-
dards and sample solutions were filtered through a
0.45 mm syringe filter (Millipore) before the injection
into the Ultra Performance Liquid Chromatography
(UPLC). Chromatographic analysis was performed using
an Acquity™ UPLC system (Waters, Milford, MA, USA)
comprising a Quaternary Solvent Manager, a Sample
Manager – TFN and a PDA detector, and the system
was operated by the Waters Empower 3 software. The
samples were analyzed with a Acquity UPLC® BEH C18
column (50 × 2.1 mm i.d.; 1.7 μm) whole through the
experiment. The PDA data were collected from 200 to
500 nm. The mobile phase consisted of acetonitrile
(solvent A) and water (solvent B) in a linear gradient
that increased from 1% to 100% of solvent A over 20 mi-
nutes. The flow rate was 0.5 ml/min and the injection
volume was 2 μl.
Animals
The protocols presented below are based on animal ex-
periments approved by the Animal Ethics Committee of
Kyung Hee University (12–015). Balb/c male mice
(6 weeks of age, weighing 20 – 25 g) were purchased
from Charles River Korea (Orient Bio, Seungnam, South
Korea). All mice were maintained under specific
pathogen-free conditions during the experiments, which
were performed according to the ethical principles and
guidelines established by the Kyung Hee University for
the care and use of experimental animals.
Animal treatment and ALI induction
The mice were randomly divided into five groups (n =
5–7/group): (1) control group: negative control mice
were sensitized and challenged with PBS alone; (2) ALI
group: mice were exposed by the intranasal route to 1.2
units of porcine pancreatic elastase (PPE; Elastin prod-
ucts, Owensville, MO, USA) on day 1 and 7 μg of LPS
(Calbiochem, Germany) on day 4 of the week for 4 con-
secutive weeks.; (3) dexa group: positive-control mice
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via an oral injection 2 hr prior to PPE and LPS stimula-
tion; (4) GJHT 100 mg/kg group: mice were adminis-
tered GJHT (100 mg/kg body wt) via an oral injection
2 hr prior to PPE and LPS stimulation; (5) GJHT
300 mg/kg group: mice were orally administered GJHT
(300 mg/kg body wt) 2 hr prior to PPE and LPS stimula-
tion. On day 32, the mice were sacrificed, and various
tissues were collected for analyses.
Analysis of lung inflammatory cells
Phosphate-buffered saline (PBS) was slowly infused into
the lungs and then withdrawn via a cannula that had
been inserted into the trachea. The numbers of total and
differential cells in the bronchoalveolar lavage (BAL)
fluid were then determined using a hemacytometer. In
addition, differential cell counts were conducted on
slides that were prepared by cytocentrifugation and Diff-
Quick staining. Approximately 500 cells were counted
per slide. The BAL fluids were then centrifuged, and the
supernatants were stored at −80°C until needed.
Measurements of IL-1β and IL-6 in BAL fluid
The levels of IL-1β and IL-6 in the BAL fluid were deter-
mined using a commercial enzyme immunoassay kit
(BD Pharmingen, USA) according to the manufacturer’s
protocols. A 96-well microtiter plate (Costar, NY, USA)
was incubated overnight at 4°C with anti-mouse IL-1β
and IL-6 monoclonal antibodies in coating buffer and
washed with PBS containing 0.05% Tween 20 (Sigma,
MO, USA). The IL-1β and IL-6-coated plates were
blocked with 5% FBS in PBS for 1 hr at 4°C and with 1%
BSA in PBS for 1 hour at room temperature, respect-
ively. BAL fluids (100 μl) were then added and incubated
for 2 hr at room temperature. Secondary peroxidase-
labeled biotinylated anti-mouse IL-1β and IL-6 monoclo-
nal antibodies were then added and incubated for 1 hour.
Finally, the plates were treated with the TMB substrate
solution (KPL, CA, USA) for 30 min, and the reaction
was stopped with the addition of the TMB stop solution
(50 μl per well). The optical density was measured at
450 nm in a microplate reader (SoftMax PRO, version
3.1 software, CA, USA). The detection limit for IL-1β
and IL-6 was 15.6 pg/ml.
Preparation of lung tissues and histology and
immunohistochemistry
Lung tissues were fixed in a 4% paraformaldehyde solu-
tion and then embedded in paraffin. For histological
examination, 4-μm sections of lung tissue were stained
sequentially with hematoxylin and eosin (H&E) or peri-
odic acid-Schiff (PAS). To immunohistochemically
evaluate neutrophil elastase (NE) and proliferating cell
nuclear antigen (PCNA), 4-um sections of lung tissuewere treated with 0.3% H2O2-methanol for 30 min to
block endogenous peroxidases, after which they were in-
cubated at 4°C overnight with anti-NE goat polyclonal
antibody (1:50 dilution; Santa Cruz Biotechnology, CA,
USA) or anti-PCNA rabbit polyclonal antibody (1:50 di-
lution; Santa Cruz Biotechnology, CA, USA). The slides
were then incubated with avidin-biotin peroxidase com-
plex (ABC kit, Vector Laboratories, CA, USA), after which
the color was developed with 3,3′-diaminobenzidine tetra-
chloride (DAB, Vector Laboratories, CA, USA). Following
immunohistochemical staining, the slides were coun-
terstained with Herris’s hematoxylin for 2 min and then
mounted with Canada balsam (Showa Chemical Co. Ltd.,
Japan). Sections with maximum cross-section of paren-
chyma were selected for morphometry using digitized
image analysis. Images were digitized and evaluated with
Image Pro-Plus 5.1 software (Media Cybernetics, Inc.
Silver Spring, MD, USA). Mean alveolar airspace was de-
termined from the sum of the lumen divided by the num-
ber of identified alveoli.
RNA preparation
The RNA was then isolated from the lung tissue using
an Rneasy® Mini Kit (Qiagen, CA, USA) according to the
manufacturer’s instructions, and the RNA was quantified
using NanoDrop (ND-1000; NanoDrop Technologies,
Inc., Wilmington, DE, USA).
Real-time RT-PCR analysis
PAS staining verification was performed via Real-time
RT-PCR analysis of Muc5AC and Muc5B genes using
LightCycler® 480 SYBR Green I Master mix and Light
Cycler 480 real-time PCR machine (Roche Applied
Science, Indianapolis, IN, USA). Expression levels of
transcripts were evaluated using the comparative CT
method (2-deltaCT). Transcript levels of GAPDH were
used for sample normalization. Results are log2-
transformed fold changes of normalized 2-deltaCT. Data
were obtained from three independent experiments and
are represented as average ± standard error. The se-
quences of the mouse primers were as follows: Muc5AC
(FW 5′-cgctaacctgccaaaagaag-3′; RW 5′-gctgaactgggg
acaacatt-3′), Muc5B (FW 5′-ccgtcctctttcccaacata-3′; RW
5′-ttggttgtcactctgcttgc-3′), and GAPDH (FW 5′-ttca
ccaccatggagaaggc-3′; RW 5′-ggcatggactgtggtcatga-3′).
Statistical analysis
Statistical analysis of the data was conducted using
Prism 5 software (GraphPad Software Inc., San Diego,
CA, USA). All values are presented as the mean ± S.E.M.
Differences between the means of the control and treat-
ment samples were determined by an one-way ANOVA
followed by Newman-Keuls post-hoc test. Results with a
p < 0.05 were considered statistically significant. The
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power analysis based on effect size (SPSS, IBM, Armonk,
NY, USA). The power (1-β) was 0.96 from one-way
ANOVA power analysis (α error = 0.05,effect size f =0.97).
Therefore total sample size (n = 26) was enough to allow
for statistically significant finding.Results
The HPLC profile of GJHT
The identified compounds of GJHT using UPLC were
listed Table 1. Five representative chemicals were clearly
identified in UPLC chromatograph (Figure 1). Identified
peaks and corresponding standard compounds were in-
dicated on the UPLC chromatogram (Figure 1).The effect of GJHT on pulmonary inflammation
To determine whether GJHT affects immune cells, mice
were subjected to a long-term exposure to PPE and LPS
(four weeks, Figure 2). At one week after the final LPS
treatment, a significant increase in the total number of
cells was observed in the ALI group when compared to
the dexamethasone-treated (1 mg/kg body wt) and GJHT-
treated (100 or 300 mg/kg body wt) groups (Figure 3). In
addition, the influx of macrophages, neutrophils, and lym-
phocytes was remarkably higher in the ALI group than in
the dexamethasone-treated (1 mg/kg body wt) and GJHT-
treated (100 or 300 mg/kg body wt) groups (Figure 3).Figure 1 The UPLC profile of Gamijinhae-tang (GJHT) extract monitored
were indicated on the UPLC chromatogram.The effects of GJHT on pro-inflammatory cytokine
production in BAL fluid
To evaluate the effects of GJHT on BAL fluid, the secre-
tion of pro-inflammatory cytokines was measured. IL-1β
and IL-6 are known to be pro-inflammatory cytokines
that contribute to LPS-induced lung inflammation.
Treatment with GJHT significantly reduced the levels of
IL-1β and IL-6 when compared to the ALI group (IL-1β;
p = 0.0029, F = 5.67, R2 = 0.52, and IL-6; p = 0.032, F = 3.23,
R2 = 0.38, Figure 4).
The effect of GJHT on histological changes in lung tissue
We also evaluated the effects of GJHT on PPE- and
LPS-induced lung damage. We stained lung sections
with hematoxylin and eosin (H&E). We found that lung
architecture of ALI group was distinct from controls
with respect to alveolar airspace. The ALI group showed
alveolar destruction, which resulted in enlarged air
spaces, indicating an emphysematous change. By con-
trast, the dexamethasone-treated (1 mg/kg body wt) and
GJHT-treated (100 or 300 mg/kg body wt) groups showed
less tissue damage (p < 0.0001, F = 69.73, and R2 = 0.94,
Figure 5).
The effect of GJHT on goblet cell hyperplasia
To evaluate the effects of GJHT on goblet cell hyperplasia
in lung tissue, the number of PAS-positive cells was evalu-
ated. The ALI group showed more PAS-positive gobletat 280 nm. Identified peaks and corresponding standard compounds
Figure 2 Schematic diagram of the experimental protocol. Animals were exposed by intranasal route to 1.2 U/kg of porcine pancreatic
elastase (PPE) on day 1 and 7 ug/kg of lipopolysaccaride (LPS) on day 4 of the week for 4 consecutive weeks. The mice were sacrificed on 7 days
at after last LPS stimulation.
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treated (1 mg/kg body wt) or GJHT-treated (100 or
300 mg/kg body wt) groups showed significantly fewer
PAS-positive cells than ALI group (p < 0.0001, F = 15.94,
and R2 = 0.76, Figure 5). PAS staining verification was
performed via Muc5AC and Muc5B mRNA expression.
The mucins Muc5AC and Muc5B are found at increased
levels in ALI group. However, dexamethasone-treated
(1 mg/kg body wt) or GJHT-treated (100 or 300 mg/kg
body wt) groups are decreased expression than ALI group
(Figure 6). These data suggest that treatment with GJHT
had a powerful preventative effect on the induced chronic
inflammatory lung disease.Figure 3 Effect of Gamijinhae-tang (GJHT) extract on immune cell pro
R2 = 0.36), macrophages (p = 0.0145, F = 4.00, and R2 = 0.43), lymphocytes (p
and R2 = 0.58) were determined in BAL fluid. Control: saline treated, ALI: PPE (
ALI + dexamethasone (Dexa), ALI + GJHT: ALI + GJHT (Gamijinhae-tang). Data
versus control and *p < 0.05, **p < 0.01 versus ALI; n = 5-7).Discussion
Exposures to environmental allergens are the main trig-
gers of asthma, while cigarette smoking is the predomin-
ant cause of COPD [21]. Both asthma and COPD are
characterized by chronic airway inflammation. The key
inflammatory cells involved in COPD (CD8+ T cells,
macrophages and neutrophils) are different from those
involved in asthma (eosinophils and CD4+ Th2 cells),
suggesting that different treatments may be required
[9,22]. However, the treatments for both of these dis-
eases may often overlap. The current standard medica-
tions for treating inflammatory lung diseases has evolved
to cocktail therapies, which are combinations of severalfiles in BAL fluid. The number of neutrophils (p = 0.042, F = 3.00, and
= 0.0049 F = 5.00, and R2 = 0.49), and total cells (p = 0.0016, F = 6.68,
porcine pancreatic elastase) + LPS (lipopolysaccaride) treated, ALI + Dexa:
are expressed as the mean number of cells ± S.E.M. (# p < 0.05, ## p < 0.01
Figure 4 Effect of Gamijinhae-tang (GJHT) extract on cytokine in BAL fluid. The levels of IL-1b and IL-6 in BAL fluid were determined by ELISA.
Control: saline treated, ALI: PPE (porcine pancreatic elastase) + LPS (lipopolysaccaride) treated, ALI + Dexa: ALI + dexamethasone (Dexa), ALI + GJHT:
ALI + GJHT (Gamijinhae-tang). Data are expressed as the mean ± S.E.M. (## p < 0.01 versus control and *p < 0.05, **p < 0.01 versus ALI; n = 5-7).
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include inhaled glucocorticosteroids, β2-adrenoceptor
agonists, leukotriene receptor antagonists, methylxan-
thines, theophylline, and others [23-26]. However, these
therapies produce potential side effects, such as growth
retardation, the induction of insulin resistance, the lossFigure 5 The effect of Gamijinhae-tang (GJHT) extract on lung tissue
eosin (magnification × 200), B) inflammatory index (p = 0.001, F = 7.14, and
(porcine pancreatic elastase) + LPS (lipopolysaccaride) treated, ALI + Dexa: A
Data are expressed as the mean ± S.E.M. (## p < 0.01 versus control and *pof bone mass, immune system suppression, cardiac co-
morbidity, nausea, emesis, gastrointestinal disturbances,
and arrhythmias, but they do not consistently ameliorate
airway inflammation in some COPD patients [27-33].
Therefore, there is a need for the development of safe
and efficacious treatments [34,35]. In the present study,damage. A) Mouse lung sections were stained with hematoxylin and
R2 = 0.59), and C) Alveolar airspace. Control: saline treated, ALI: PPE
LI + dexamethasone (Dexa), ALI + GJHT: ALI + GJHT(Gamijinhae-tang).
< 0.05, **p < 0.01 versus ALI; n = 5-7).
Figure 6 The effect of Gamijinhae-tang (GJHT) extract on goblet cell and musins. A) Mouse lung sections were stained with PAS
(magnification × 400), B) goblet cell (%), and C) Muc5AC and Muc5B mRNA expression. Muc5AC and Muc5B mRNA expression were analyzed by
quantitative real-time PCR. Expression levels of Muc5AC and Muc5B mRNA were normalized to GAPDH and expressed as the relative quantity to
controls. Control: saline treated, ALI: PPE (porcine pancreatic elastase) + LPS (lipopolysaccaride) treated, ALI + Dexa: ALI + dexamethasone (Dexa),
ALI + GJHT: ALI + GJHT (Gamijinhae-tang). Data are expressed as the mean ± S.E.M. (## p < 0.01 versus control and *p < 0.05, **p < 0.01 versus ALI;
n = 5-7). The statistic power for Muc5AC; p = 0.0039, F = 7.89, and R2 = 0.76, and for Muc5B; p = 0.0042, F = 7.70, and R2 = 0.75.
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tural and functional changes that are typical of COPD,
including airway remodeling, diffuse lung inflammation,
goblet cell hyperplasia, alveolar enlargement, and in-
creased numbers of neutrophils, lymphocytes, and mac-
rophages in the airways and alveoli. In addition, in the
airways the mucins Muc5AC and Muc5B are found at
increased levels in both asthmatic and COPD subjects[36,37]. Mucin hypersecretion is associated with abnor-
mal epithelial cell growth and differentiation, both in-
flammatory mediators and growth factors may be
involved in the stimulation of mucin production from
goblet cells [38]. However, GJHT treatment ameliorated
the lung structural and functional changes in the PPE
and LPS exposure model. These results may suggest
that GJHT is a useful therapeutic agent that prevents
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COPD.
The components of GJHT have been shown to have
various biological effects. Rehmannia glutinosa, a major
component of GJHT, possesses thrombolytic, hypergly-
cemic, and anti-inflammatory activities and improves
renal functions in diabetic nephropathy [39-43]. In
addition, this herb has been reported to suppress the
production of TNF-α and IL-1 in mouse astrocytes [44].
Atractylodes macrocephala, another component of
GJHT, possesses antioxidant, hepatoprotective, anti-
inflammatory, anti-allergic, antithrombotic, antiviral and
anticarcinogenic activities [45-47]. Angelica sinensis is
well known to have strong immune regulatory effects,
such as antiviral activities and improving immune func-
tion by increasing CD4+ cells and the CD4+/CD8+ ratio
[48]. Liriope platyphylla has been used to treat asthma
and bronchial and lung inflammation [49]. In addition,
this compound possesses various therapeutic effects for
conditions such as obesity, diabetes, inflammation and
neurodegenerative disease [50-53]. Scutellaria baicalensis
has been used to treat inflammation, cancer, bacterial and
viral infections of the respiratory and gastrointestinal
tracts [54-56]. Some of the components of GJHT are
reported to possess anti-cancer effects for various types
of malignancy via distinct molecular mechanisms and in-
clude Raphanus sativus [57,58], Astragalus membranaceus
[59-61], Poria cocos [62], Citrus unshiu [63], Platycodon
grandiflorum [64] and Anthriscus sylvestris [65]. The
therapeutic potency of GJHT should be attributed to its
combined and synergistic effects on multiple targets as a
result of the diverse components of GJHT. In addition,
according to the formula suggested by US Food and Drug
Administration [66], human equivalent dose (HED) calcu-
lated from mice dosage (100 mg/kg and 300 mg/kg) used
in this study was 480 mg/60 kg and 1440 mg/60 kg in hu-
man, respectively. We believe that these amounts of GJHT
would be applicable dosages to human.
The morphological and inflammatory changes were
accompanied by increases in lung IL-1β and IL-6, as ob-
served in humans with COPD [67,68]. A recent genetic
analysis study demonstrated that IL6, IL1RN, IL1B, and
IFNG genes were risk factors for the accelerated decline
of lung function or baseline lung function in COPD pa-
tients [69]. Importantly, their study demonstrated a sig-
nificant association between IL6 and an IL6-smoking
interaction in cardiovascular disease [69]. In addition,
high levels of serum or sputum IL-6 have been associ-
ated with impaired lung function, pulmonary infections,
exacerbations, and skeletal muscle weakness in COPD
patients [70-74]. Experimental studies have shown that
IL-6 overexpression in the murine lung results in
emphysema-like airspace enlargement and airway in-
flammation [75]. In the present study, GJHT treatmentsignificantly reduced the amounts of IL-1β and IL-6 in
the airway, suggesting that the anti-inflammatory effect
of GJHT can be attributed to the suppression of
proinflammatory cytokine production in the lung. Even
though the power calculation result demonstrated that
the animal number used in this study was enough to tell
the statistical importance, the sample size of this study
was relatively small (n = 5,6 each group) that might mis-
lead the data interpretation. To overcome such limita-
tions, additional researches investigating the mechanism
of Gamijinhae-tang on lung inflammation are necessary.
Conclusions
Taken together, the results of this study suggest that
GJHT significantly reduces PPE- and LPS-induced lung
inflammation. The anti-inflammatory effects of GJHT
indicate that it has therapeutic potential for chronic ob-
structive pulmonary disease.
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